Quantitative assessment of the adherence to sublingual immunotherapy

Lombardi, Carlo; Gani, Federica; Landi, Massimo; Falagiani, P.; Bruno, M.; Canonica, Giorgio Walter; Passalacqua, Giovanni

doi:10.1016/j.jaci.2004.03.013

Cited by 76 publications

(57 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…data are in agreement with several previously published studies of patients with PAR, which have reported the rates of around 70-80%[10,15,[17][18][19][20][21][22]. Another study has reported a higher compliance of approximately 97%[20].However, in that study, the patients counted the pills themselves and reported via a Variations caused by the method of compliance measurement were apparent in our study.…”

supporting

confidence: 93%

“…The available data on the patient adherence to allergen-specific immunotherapy are often conflicting [11,12]. In particular, in allergic rhinitis, compliance rates for sublingual administration range between 70% and 97% [10,[13][14][15][16][17][18][19][20][21][22]. This wide variation might be explained by differences in the characteristics and methodology of the studies, such as the population profiles and the definition of compliance [23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis

Malet¹,

Azpeitia

Gutiérrez

et al. 2016

Adv Ther

View full text Add to dashboard Cite

show abstract

supporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis

Malet¹,

Azpeitia

Gutiérrez

et al. 2016

Adv Ther

View full text Add to dashboard Cite

show abstract

“…No studies have specifically examined adherence to the SLIT regimen in the pediatric population; however, three studies in a mixed-age population have assessed compliance with either unscheduled telephone requests to count remaining tablets [68,69] or measurement of remaining extract on clinic visits [70•]. High compliance, defined as taking medications more than 80% or 90% of the time, was reported in 72% [69], 76% [70•], and 97% [68] of patients.…”

Section: Adherencementioning

confidence: 99%

“…High compliance, defined as taking medications more than 80% or 90% of the time, was reported in 72% [69], 76% [70•], and 97% [68] of patients. One study prospectively investigated the compliance with three immunotherapy methods-SLIT, SCIT, and nasal immunotherapy-in 2774 children (ages 6 to 15 years) by measuring the number of patients who withdrew before completing 3 years of treatment [71].…”

Section: Adherencementioning

confidence: 99%

Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerations

Cox

2007

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Specific allergen immunotherapy (SIT) is the only disease-modifying treatment for allergic rhinitis and asthma. Subcutaneous immunotherapy (SCIT) is the only method with a US Food and Drug Administration (FDA)-approved formulation, but safety concerns limit administration to medical facilities. Sublingual immunotherapy (SLIT), under investigation in the United States, appears to have a more favorable safety profile, which may expand its use to populations generally not treated with SIT (eg, young children). This paper reviews SLIT studies that were specifically limited to the pediatric population. Most demonstrated evidence of clinical efficacy, but approximately 29% failed to demonstrate efficacy in symptom and medication scores in the first treatment year. Efficacy was seen in a broad range of allergen doses, but optimal dose range has not been established. SLIT appeared to be well tolerated in children as young as 2 years, but serious adverse reactions, including anaphylaxis, were reported. SLIT is a promising immunotherapy that may expand the population receiving SIT because of the convenience of home administration due to its favorable safety profile. However, questions remain unanswered, including optimal therapeutic dose.

show abstract

“…One of the criticisms that has always been brought against SLIT is that thepatients’ adherence to the therapy is uncertain, because it is self-administered. A recent systematic real-life study has shown that therapy adherence is very high (over 95%), independent of the patients’ socioeconomic characteristics [25]. A randomized, controlled study that involved more than 500 patients has furthermore demonstrated that SLIT can prevent new sensibilizations as well as subcutaneous SIT [26].…”

Section: Introductionmentioning

confidence: 99%

Long-Lasting Effects of Sublingual Immunotherapy for House Dust Mites in Allergic Rhinitis with Bronchial Hyperreactivity: A Long-Term (13-Year) Retrospective Study in Real Life

Marogna

Bruno

Massolo

et al. 2006

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: Subcutaneous immunotherapy for respiratory allergy has shown a long lasting efficacy after its discontinuation, whereas evidence in the case of sublingual immunotherapy (SLIT) is weak. This retrospective study evaluates whether SLIT exerts a long-lasting effect and whether it relates to its duration. Methods: Sixty-five patients allergic to mite and positive to methacholine challenge 13 years ago were studied. Twelve (control group, SLIT 0) were treated for 4 years only with standard pharmacological therapy (SPT), while 53 received SLIT and SPT. Among these, four groups were identified according to SLIT duration. Fifteen patients were treated for 1 year (SLIT 1), 10 for 2 (SLIT 2), 14 for 3 (SLIT 3) and 14 for 4 years (SLIT 4). Clinical parameters (symptom monthly score, SMS), bronchial reactivity and FEV₁ were evaluated in 1992 (run-in), 1993 (baseline) and every 2 years from 1997 to 2005. Results: Two to 3 years after the treatment ended, a positive effect on SMS, but not methacholine challenge and FEV₁, was seen in the SLIT groups versus SLIT 0. At this time interval an effect on methacholine challenge was also seen in SLIT 3. After 7–8 years a significant difference was seen for SMS, i.e., it was significantly better in SLIT 4 than in the other groups, while bronchial reactivity was still improved in SLIT 1, 3 and 4 only after 5–6 years. Conclusions:The effects of a 4-year SLIT on clinical parameters but not bronchial reactivity and FEV₁ last 7–8 years after its discontinuation. SLIT shorter than 4 years yields proportionally less impressive results.

show abstract

Quantitative assessment of the adherence to sublingual immunotherapy

Cited by 76 publications

References 7 publications

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis

Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerations

Long-Lasting Effects of Sublingual Immunotherapy for House Dust Mites in Allergic Rhinitis with Bronchial Hyperreactivity: A Long-Term (13-Year) Retrospective Study in Real Life

Contact Info

Product

Resources

About